In short
This article examines the use of elvitegravir, an integrase inhibitor, in clinical trials for HIV treatment. Elvitegravir is often studied as part of combination antiretroviral therapy regimens, particularly in the single-tablet formulation Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide). The trials investigate elvitegravir's efficacy, safety, and potential advantages compared to other HIV medications in various patient populations.
At a glance
- Drug Formulations
- Elvitegravir studied in combination therapies like Genvoya and Stribild
- Patient Populations
- Treatment-naive, treatment-experienced, HIV/HBV co-infected, HIV-2 infected
- Primary Outcomes
- Viral suppression, CD4 count changes, safety/tolerability
- Comparator Treatments
- Efavirenz-based regimens, raltegravir-based regimens
- Duration of Studies
- Typically 48-96 weeks
- Special Considerations
- Neuropsychiatric effects, bone/kidney health, drug interactions
What is elvitegravir?
Elvitegravir is an antiretroviral medication used to treat HIV-1 infection. It belongs to a class of drugs called integrase strand transfer inhibitors (INSTIs). Elvitegravir is often prescribed as part of combination antiretroviral therapy (ART) regimens to suppress HIV viral replication and improve immune function in people living with HIV.
How Elvitegravir Works
Elvitegravir works by inhibiting the HIV integrase enzyme, which is responsible for inserting the viral genetic material into the DNA of host cells. By blocking this crucial step in the HIV life cycle, elvitegravir prevents the virus from replicating and infecting new cells.
Uses of elvitegravir
Elvitegravir is primarily used for:
- Treatment of HIV-1 infection in adults and adolescents
- Part of initial antiretroviral therapy for treatment-naïve patients
- Switching therapy for virologically suppressed patients
It is not approved for use in HIV-2 infection, although research is ongoing in this area.
Elvitegravir Formulations
Elvitegravir is available in several fixed-dose combination tablets:
- Stribild: Contains elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate
- Genvoya: Contains elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide
These single-tablet regimens simplify dosing and may improve adherence to treatment.
Effectiveness
Clinical trials have demonstrated the effectiveness of elvitegravir-containing regimens in achieving and maintaining viral suppression in HIV-1 infected patients. For example:
- In a study comparing elvitegravir to raltegravir (another integrase inhibitor), both drugs showed similar efficacy in achieving viral suppression (HIV-1 RNA < 50 copies/mL) at 48 weeks.
- A trial evaluating Genvoya (containing elvitegravir) showed that 91.7% of HIV/HBV co-infected patients maintained or achieved virologic suppression for both HIV and HBV at 48 weeks of therapy.
Side Effects
Common side effects of elvitegravir-containing regimens may include:
- Nausea
- Diarrhea
- Headache
- Fatigue
Some patients may experience neurological or psychiatric side effects. A study found that the frequency of these complaints in patients taking elvitegravir reaches on average 20-30% during clinical trials. These may include:
- Sleep disturbances
- Anxiety
- Depression
- Dizziness
Drug Interactions
Elvitegravir is often co-formulated with cobicistat, a pharmacokinetic enhancer. This combination can lead to significant drug interactions. Patients should inform their healthcare providers about all medications they are taking, including over-the-counter drugs and supplements.
Use in Special Populations
Elvitegravir-containing regimens have shown promise in certain special populations:
- HIV/HBV co-infection: Genvoya (containing elvitegravir) has demonstrated efficacy in patients co-infected with HIV and hepatitis B virus.
- Renal impairment: Some elvitegravir-containing regimens (e.g., Genvoya) may be suitable for patients with mild to moderate renal impairment.
Ongoing Research
Research on elvitegravir is ongoing, including:
- Evaluation of its use in HIV-2 infection
- Comparison with other antiretroviral regimens for post-exposure prophylaxis (PEP)
- Assessment of its long-term safety and efficacy
In conclusion, elvitegravir is an important component of modern HIV treatment regimens. Its effectiveness, convenient dosing in single-tablet formulations, and generally favorable side effect profile make it a valuable option for many patients living with HIV. However, as with all medications, its use should be carefully considered and monitored by healthcare professionals.
